At 4:47 p.m. Thursday a Boston federal jury returned the first plaintiff verdict against a pharmaceutical company in a pay-for-delay class action since the Supreme Court greenlit the theory in 2013. $821.7 million of the award trebles to roughly $2.47 billion. The opt-out geometry — CVS and Walgreens captured $312 million combined, the entire end-payor class split $63.2 million — is the template every carrier antitrust unit is reading this weekend.
At 4:47 p.m. on Thursday, May 21, 2026, the foreperson of a federal jury in Boston rose and read out a number that made Takeda Pharmaceutical's lead trial counsel sit very still: eight hundred eighty-five million dollars. The jurors had spent five weeks watching Kristen Johnson walk them through what she called "a $210 million payoff" wired between two drugmakers to keep a cheaper version of the constipation drug Amitiza off pharmacy shelves until January 2021. They returned with the first plaintiff verdict against a pharmaceutical company in a pay-for-delay class action since the Supreme Court greenlit the theory in 2013. Under federal antitrust law, $821.7 million of the award trebles automatically to roughly $2.47 billion. The number, reported within the hour by Insurance Journal, kept climbing on the screens of carrier general counsel from Hartford to Bloomfield.
The case sat in the U.S. District Court for the District of Massachusetts under the consolidated caption In re Amitiza Antitrust Litigation. Johnson, of Hagens Berman, ran point for the direct purchaser class. Jonathan Stratton handled the retailer track. Across the aisle sat Joshua Barlow, defending Takeda through a five-week trial that turned on a single 2014 agreement: Par Pharmaceutical, the would-be generic challenger, would drop its patent fight in exchange for a payment and a January 2021 launch date. Plaintiffs called it a reverse payment. Takeda called it a patent settlement.
Johnson, in closing, told jurors: "This verdict makes clear that pharmaceutical companies cannot buy their way out of competition." The jury agreed in three columns. Direct purchasers, the wholesalers who buy from manufacturers, took $474.9 million. The end-payor class, which is where the property and casualty carriers, health funds, and ERISA plans live, took $63.2 million. Individual retailers who opted out and sued on their own took $346.8 million, with CVS recovering $191 million and Walgreens recovering $121 million.
The shape of the $885 million award is itself the story for any subrogation lawyer reading the docket Friday morning. CVS and Walgreens did not stay in the class. They hired their own counsel, sat at their own counsel table, and walked out with per-plaintiff recoveries roughly three times larger than what their fellow retailers split inside the class. The math is not subtle. Two named retailers, acting individually, captured $312 million of the verdict. The entire end-payor class, which includes every major health insurer that paid an Amitiza claim between 2014 and 2021, split $63.2 million.
Trial drama, nuclear verdicts, and the plaintiff-firm tactics behind them. Court-reporter prose, no consultant filler. Read by litigation leaders at F500 legal departments and national carriers. Free.
Two named retailers, acting individually, captured $312 million of the verdict. The entire end-payor class split $63.2 million. The ratio is the template.
That ratio is the template. It is also the conversation happening this weekend inside every carrier antitrust unit that previously treated pay-for-delay recovery as a passive class-membership exercise. The Hagens Berman complaint, the docket on PACER and mirrored on CourtListener, and the Hagens Berman case page all show the named opt-out plaintiffs filed substantively identical pleadings to the class, then tried the case in parallel. The opt-out machinery is not exotic. It is paperwork and a willingness to seat counsel.
Barlow's defense leaned on the Hatch-Waxman framework: Takeda's underlying patent was presumed valid, the Par settlement preserved a launch date earlier than patent expiration, and the payment, in Takeda's telling, reflected litigation risk rather than monopoly rent. The jury was not persuaded. They were shown internal Takeda projections of generic erosion, the timing of the payment alongside the dismissal of Par's paragraph IV challenge, and the price curve Amitiza traveled between 2014 and 2021. Generic linaclotide and lubiprostone substitutes arrived only after the agreed January 2021 date. The premium consumers, pharmacies, and end-payors paid in the interim is what plaintiffs metered against the $885 million figure.
Takeda issued a one-paragraph statement after the verdict announcing it would seek post-trial relief and, if denied, an appeal to the First Circuit. The company's stock closed before the verdict and will reopen to it Friday. Internal counsel familiar with the trial team's strategy expect motions for judgment as a matter of law and remittitur within the standard twenty-eight day post-verdict window, with the appeal docketed before the First Circuit by late summer.
The class verdict of $63.2 million for end-payors will be distributed through a claims administrator on a pro rata basis tied to documented Amitiza paid claims. Carriers who archived pharmacy benefit manager remittance data from 2014 through 2021 will receive checks. Carriers who did not, or who relied on PBM aggregators to file class proofs of claim, will receive smaller checks or none. The Hagens Berman administrator is expected to publish a claim deadline within sixty days under the standard schedule for antitrust class recoveries.
Two separate dockets matter for what happens next. The First Circuit will hear Takeda's appeal on the reverse-payment legal standard sometime in 2027. And every active pay-for-delay case currently pending, including the Humira, Restasis, and Bystolic dockets tracked on the FTC's pharmaceutical antitrust page, now carries a $885 million data point that did not exist on Wednesday.
The Executive Briefing is six questions. It shows you exactly where the gaps are.
Take the Executive Briefing →Trial drama, nuclear verdicts, and the plaintiff-firm tactics behind them. Court-reporter prose, no consultant filler. Read by litigation leaders at F500 legal departments and national carriers. Free.